The effects of therapeutic agents against hypertension, dyslipidemia or diabetes on cholesterol efflux capacity by HDL cholesterol

The effects of therapeutic agents against hypertension, dyslipidemia or diabetes on cholesterol efflux capacity by HDL cholesterol - The effects of therapeutic agents on cholesterol efflux capacity by HDL cholesterol

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000005734

Enrollment

120

Registered

2014-01-01

Start date

2011-08-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertension, Dyslipidemia, Diabetes

Interventions

Patients start to take Norvasc 5mg/day for hypertension. Patients start to take Olmetec 20mg/day for hypertension. Patients start to take Micardis 40mg/day for hypertension. Patients start to take Li

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients who are diagnosed as hypertension, hypercholesteremia, hypertriglicemia, or type 2 diabetes according to their crieteria, take no medicine for each disease and consent to participate in this study

Exclusion criteria

Exclusion criteria: .Patients who have allergy for taking medicine .Patients who have hepatic disorder(AST or ALT> 100IU/L), biliary duct obstruction and the following diseases with decreased hepatic function (acute hepatitis, acute exacerbation of chronic hepatitis, liver cirrhosis, liver cancer and jaundice) .eGFR<60ml/min/1.73m2 .Diabetes patients treated with insulin. .Female patients with the possibility of pregnancy .Patients excluded by doctors

Design outcomes

Primary

Measure	Time frame
Cholesterol efflux capacity by HDL cholesterol	—

Secondary

Measure	Time frame
pre beta-1, ApoA-I, ApoA-II, oxidative stress marker(T-BARS) etc.	—

Countries

Japan

Contacts

Public ContactKoh Ono

Graduate school of medicine, Kyoto University Department of Cardiovascular medicine

kohono@kuhp.kyoto-u.ac.jp075-751-3190

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026